Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public)
29 November 2023 - 4:39AM
Edgar (US Regulatory)
|
|
|
| Schedule of Investments (unaudited)
September 30, 2023 |
|
BlackRock Health Sciences Term Trust (BMEZ)
(Percentages shown are based on Net Assets) |
|
|
|
|
|
|
|
|
|
Security |
|
Shares |
|
|
Value |
|
|
| Common Stocks |
|
|
|
| Biotechnology — 42.4% |
|
|
|
|
| 4D Molecular Therapeutics, Inc.(a) |
|
|
95,330 |
|
|
$ |
1,213,551 |
|
| Abbisko Cayman Ltd., (Acquired 10/29/21, Cost:
$14,841,983)(b) |
|
|
10,378,250 |
|
|
|
3,538,514 |
|
| Abcam PLC, ADR(a) |
|
|
976,460 |
|
|
|
22,097,290 |
|
| ABCURO, Series B(c) |
|
|
546,477 |
|
|
|
3,000,159 |
|
| Acumen Pharmaceuticals, Inc.(a) |
|
|
72,721 |
|
|
|
301,792 |
|
| Affinivax, Inc., (Acquired 08/18/22, Cost: $0)(b)(c)
|
|
|
183,164 |
|
|
|
2,425,090 |
|
| Alkermes PLC(a) |
|
|
1,056,985 |
|
|
|
29,606,150 |
|
| Allakos, Inc.(a) |
|
|
136,405 |
|
|
|
309,639 |
|
| Alnylam Pharmaceuticals, Inc.(a)(d) |
|
|
153,792 |
|
|
|
27,236,563 |
|
| Amgen, Inc. |
|
|
151,320 |
|
|
|
40,668,763 |
|
| Annexon, Inc.(a) |
|
|
237,835 |
|
|
|
561,291 |
|
| Antengene Corp. Ltd. |
|
|
5,019,274 |
|
|
|
766,264 |
|
| Apellis Pharmaceuticals, Inc.(a) |
|
|
51,390 |
|
|
|
1,954,876 |
|
| Apogee Therapeutics, Inc. |
|
|
218,677 |
|
|
|
4,657,820 |
|
| Arcturus Therapeutics Holdings, Inc.(a) |
|
|
103,675 |
|
|
|
2,648,896 |
|
| Arcus Biosciences, Inc.(a) |
|
|
169,790 |
|
|
|
3,047,731 |
|
| Argenx SE, ADR(a) |
|
|
96,877 |
|
|
|
47,627,640 |
|
| Arrowhead Pharmaceuticals, Inc.(a) |
|
|
81,025 |
|
|
|
2,177,142 |
|
| Aura Biosciences, Inc.(a) |
|
|
165,565 |
|
|
|
1,485,118 |
|
| Bavarian Nordic A/S(a)(e) |
|
|
75,320 |
|
|
|
1,685,322 |
|
| BeiGene Ltd., ADR(a) |
|
|
68,555 |
|
|
|
12,330,988 |
|
| Biogen, Inc.(a) |
|
|
83,480 |
|
|
|
21,455,195 |
|
| Biohaven Ltd.(a) |
|
|
99,155 |
|
|
|
2,579,022 |
|
| BioMarin Pharmaceutical, Inc.(a) |
|
|
420,758 |
|
|
|
37,228,668 |
|
| Biomea Fusion, Inc.(a)(e) |
|
|
146,215 |
|
|
|
2,011,918 |
|
| Black Diamond Therapeutics, Inc.(a) |
|
|
833,550 |
|
|
|
2,392,289 |
|
| Blueprint Medicines Corp.(a) |
|
|
322,440 |
|
|
|
16,192,937 |
|
| Bridgebio Pharma, Inc.(a) |
|
|
66,595 |
|
|
|
1,756,110 |
|
| Cabaletta Bio, Inc.(a) |
|
|
85,340 |
|
|
|
1,298,875 |
|
| Cerevel Therapeutics Holdings, Inc.(a) |
|
|
266,656 |
|
|
|
5,821,100 |
|
| Connect Biopharma Holdings Ltd.(a) |
|
|
1,125,262 |
|
|
|
872,641 |
|
| CRISPR Therapeutics AG(a)(e) |
|
|
47,805 |
|
|
|
2,169,869 |
|
| CureVac NV(a) |
|
|
257,233 |
|
|
|
1,756,901 |
|
| Everest Medicines Ltd. |
|
|
3,113,667 |
|
|
|
9,903,749 |
|
| Exact Sciences Corp.(a) |
|
|
129,770 |
|
|
|
8,852,909 |
|
| Exelixis, Inc.(a) |
|
|
599,320 |
|
|
|
13,095,142 |
|
| Frequency Therapeutics, Inc.(a) |
|
|
231,775 |
|
|
|
84,853 |
|
| Galapagos NV, ADR(a) |
|
|
74,410 |
|
|
|
2,570,866 |
|
| Genesis Therapeutics, Series B, (Acquired 08/10/23,
Cost: $6,999,996)(b)(c) |
|
|
1,370,506 |
|
|
|
7,003,286 |
|
| Genmab A/S(a) |
|
|
34,827 |
|
|
|
12,330,519 |
|
| Genmab A/S, ADR(a)(e) |
|
|
114,086 |
|
|
|
4,023,813 |
|
| Gilead Sciences, Inc. |
|
|
254,765 |
|
|
|
19,092,089 |
|
| Halozyme Therapeutics, Inc.(a) |
|
|
158,300 |
|
|
|
6,047,060 |
|
| Horizon Therapeutics PLC(a) |
|
|
75,466 |
|
|
|
8,730,662 |
|
| Immuneering Corp., Class A(a) |
|
|
696,696 |
|
|
|
5,350,625 |
|
| Immunocore Holdings PLC, ADR(a) |
|
|
59,868 |
|
|
|
3,107,149 |
|
| Immunocore Holdings PLC |
|
|
321,900 |
|
|
|
16,706,610 |
|
| ImmunoGen, Inc.(a) |
|
|
333,839 |
|
|
|
5,298,025 |
|
| Incyte Corp.(a) |
|
|
227,420 |
|
|
|
13,138,053 |
|
| Ionis Pharmaceuticals, Inc.(a) |
|
|
468,185 |
|
|
|
21,236,872 |
|
| Iovance Biotherapeutics, Inc.(a) |
|
|
168,215 |
|
|
|
765,378 |
|
| Kartos Therapeutics, Series C, (Acquired 08/22/23,
Cost: $7,539,875)(b)(c) |
|
|
1,333,783 |
|
|
|
7,535,874 |
|
| Karuna Therapeutics, Inc.(a) |
|
|
21,650 |
|
|
|
3,660,798 |
|
| Keros Therapeutics, Inc.(a) |
|
|
124,317 |
|
|
|
3,963,226 |
|
| Kinnate Biopharma, Inc.(a) |
|
|
196,773 |
|
|
|
275,482 |
|
| Kronos Bio, Inc.(a) |
|
|
284,272 |
|
|
|
369,554 |
|
|
|
|
|
|
|
|
|
|
Security |
|
Shares |
|
|
Value |
|
|
|
| Biotechnology (continued) |
|
|
|
|
| Legend Biotech Corp., ADR(a)(e) |
|
|
316,032 |
|
|
$ |
21,227,869 |
|
| LianBio, Series A, ADR(a) |
|
|
615,188 |
|
|
|
916,630 |
|
| MacroGenics, Inc.(a) |
|
|
190,555 |
|
|
|
887,986 |
|
| Merus NV(a) |
|
|
411,972 |
|
|
|
9,714,300 |
|
| Mirati Therapeutics, Inc.(a) |
|
|
180,175 |
|
|
|
7,848,423 |
|
| Monte Rosa Therapeutics, Inc.(a) |
|
|
764,573 |
|
|
|
3,662,305 |
|
| MoonLake Immunotherapeutics, Class A(a)(e)
|
|
|
256,816 |
|
|
|
14,638,512 |
|
| Morphic Holding, Inc.(a) |
|
|
75,190 |
|
|
|
1,722,603 |
|
| MorphoSys AG(a) |
|
|
50,810 |
|
|
|
1,382,284 |
|
| Neurocrine Biosciences, Inc.(a) |
|
|
165,520 |
|
|
|
18,621,000 |
|
| Nuvalent, Inc., Class A(a) |
|
|
241,500 |
|
|
|
11,101,755 |
|
| Omega Therapeutics, Inc.(a) |
|
|
55,871 |
|
|
|
120,123 |
|
| PMV Pharmaceuticals, Inc.(a) |
|
|
305,830 |
|
|
|
1,877,796 |
|
| Prime Medicine, Inc.(a) |
|
|
412,139 |
|
|
|
3,931,806 |
|
| Protagonist Therapeutics, Inc.(a) |
|
|
421,725 |
|
|
|
7,034,373 |
|
| Prothena Corp. PLC(a) |
|
|
72,791 |
|
|
|
3,512,166 |
|
| PTC Therapeutics, Inc.(a)(e) |
|
|
225,815 |
|
|
|
5,060,514 |
|
| REVOLUTION Medicines, Inc.(a) |
|
|
377,632 |
|
|
|
10,452,854 |
|
| Rhythm Pharmaceuticals, Inc.(a)(e) |
|
|
683,675 |
|
|
|
15,673,249 |
|
| Rocket Pharmaceuticals, Inc.(a) |
|
|
252,097 |
|
|
|
5,165,468 |
|
| Sarepta Therapeutics, Inc.(a)(d) |
|
|
237,759 |
|
|
|
28,821,146 |
|
| Seagen, Inc.(a)(d)(f) |
|
|
106,455 |
|
|
|
22,584,428 |
|
| Tenaya Therapeutics, Inc.(a) |
|
|
165,729 |
|
|
|
422,609 |
|
| TScan Therapeutics, Inc.(a) |
|
|
1,204,397 |
|
|
|
3,083,256 |
|
| Twist Bioscience Corp.(a) |
|
|
130,265 |
|
|
|
2,639,169 |
|
| Ultragenyx Pharmaceutical, Inc.(a) |
|
|
99,375 |
|
|
|
3,542,719 |
|
| United Therapeutics Corp.(a)(d) |
|
|
55,704 |
|
|
|
12,581,862 |
|
| Vaxcyte, Inc.(a)(e) |
|
|
148,645 |
|
|
|
7,577,922 |
|
| Vertex Pharmaceuticals, Inc.(a)(d)(f) |
|
|
176,460 |
|
|
|
61,362,200 |
|
| Viking Therapeutics, Inc.(a) |
|
|
235,245 |
|
|
|
2,604,162 |
|
| Voyager Therapeutics, Inc.(a)(e) |
|
|
164,865 |
|
|
|
1,277,704 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
769,067,911 |
|
|
|
| Electronic Equipment, Instruments & Components — 0.1% |
|
|
|
|
| 908 Devices, Inc.(a) |
|
|
274,084 |
|
|
|
1,825,399 |
|
|
|
|
|
|
|
|
|
|
|
| Health Care Equipment & Supplies — 22.6% |
|
| Alcon, Inc. |
|
|
668,915 |
|
|
|
51,546,590 |
|
| Align Technology, Inc.(a)(f) |
|
|
135,670 |
|
|
|
41,422,764 |
|
| Becton Dickinson & Co. |
|
|
40,325 |
|
|
|
10,425,222 |
|
| Boston Scientific Corp.(a) |
|
|
455,830 |
|
|
|
24,067,824 |
|
| CONMED Corp. |
|
|
98,215 |
|
|
|
9,904,983 |
|
| ConvaTec Group PLC(g) |
|
|
4,411,215 |
|
|
|
11,690,025 |
|
| Cooper Cos., Inc. |
|
|
99,160 |
|
|
|
31,533,872 |
|
| Dexcom, Inc.(a) |
|
|
119,929 |
|
|
|
11,189,376 |
|
| Glaukos Corp.(a) |
|
|
110,325 |
|
|
|
8,301,956 |
|
| Hologic, Inc.(a)(d) |
|
|
194,620 |
|
|
|
13,506,628 |
|
| Inspire Medical Systems, Inc.(a) |
|
|
48,555 |
|
|
|
9,635,254 |
|
| Intuitive Surgical, Inc.(a)(d) |
|
|
136,568 |
|
|
|
39,917,461 |
|
| Masimo Corp.(a) |
|
|
145,470 |
|
|
|
12,754,810 |
|
| Novocure Ltd.(a) |
|
|
213,335 |
|
|
|
3,445,360 |
|
| Nyxoah SA(a)(e) |
|
|
648,041 |
|
|
|
4,471,483 |
|
| Omnicell, Inc.(a) |
|
|
122,670 |
|
|
|
5,525,057 |
|
| Orchestra BioMed Holdings, Inc.(a)(e) |
|
|
233,344 |
|
|
|
2,034,760 |
|
| Penumbra, Inc.(a) |
|
|
118,808 |
|
|
|
28,740,843 |
|
| Pulmonx Corp.(a) |
|
|
335,566 |
|
|
|
3,466,397 |
|
| Shockwave Medical, Inc.(a) |
|
|
65,120 |
|
|
|
12,965,392 |
|
| SI-BONE,
Inc.(a) |
|
|
204,910 |
|
|
|
4,352,288 |
|
| STAAR Surgical Co.(a) |
|
|
73,525 |
|
|
|
2,954,234 |
|
| STERIS PLC |
|
|
158,575 |
|
|
|
34,794,526 |
|
|
|
|
| Schedule of Investments (unaudited) (continued)
September 30, 2023 |
|
BlackRock Health Sciences Term Trust (BMEZ)
(Percentages shown are based on Net Assets) |
|
|
|
|
|
|
|
|
|
Security |
|
Shares |
|
|
Value |
|
|
| Health Care Equipment & Supplies (continued) |
|
| Straumann Holding AG, Registered Shares |
|
|
96,155 |
|
|
$ |
12,238,506 |
|
| Stryker Corp. |
|
|
68,240 |
|
|
|
18,647,945 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
409,533,556 |
|
|
|
| Health Care Providers & Services — 5.8% |
|
|
|
|
| Adicon Holdings Ltd., (Acquired 07/19/23, Cost: $17,840,000)(b) |
|
|
10,696,226 |
|
|
|
21,301,833 |
|
| Adicon Holdings Ltd. |
|
|
1,431,000 |
|
|
|
2,923,783 |
|
| Cencora, Inc. |
|
|
193,455 |
|
|
|
34,816,096 |
|
| Chemed Corp. |
|
|
10,662 |
|
|
|
5,541,042 |
|
| Encompass Health Corp.(d) |
|
|
112,563 |
|
|
|
7,559,731 |
|
| Guardant Health, Inc.(a) |
|
|
196,470 |
|
|
|
5,823,371 |
|
| Humana, Inc. |
|
|
18,270 |
|
|
|
8,888,721 |
|
| Kindstar Globalgene Technology, Inc.(a)(g)
|
|
|
4,092,500 |
|
|
|
825,717 |
|
| McKesson Corp. |
|
|
38,905 |
|
|
|
16,917,839 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
104,598,133 |
|
|
|
| Health Care Technology — 0.0% |
|
|
|
|
| Sophia Genetics SA(a)(e) |
|
|
291,485 |
|
|
|
743,287 |
|
|
|
|
|
|
|
|
|
|
|
|
| Life Sciences Tools & Services — 11.3% |
|
|
|
|
| 10X Genomics, Inc., Class A(a) |
|
|
196,435 |
|
|
|
8,102,944 |
|
| Avantor, Inc.(a)(d) |
|
|
664,444 |
|
|
|
14,006,480 |
|
| Bio-Rad Laboratories, Inc., Series L, Class A(a) |
|
|
20,190 |
|
|
|
7,237,105 |
|
| Bio-Techne Corp. |
|
|
201,360 |
|
|
|
13,706,575 |
|
| Bruker Corp., Series A |
|
|
185,257 |
|
|
|
11,541,511 |
|
| Gerresheimer AG |
|
|
243,305 |
|
|
|
25,493,789 |
|
| Mettler-Toledo International, Inc.(a) |
|
|
11,590 |
|
|
|
12,842,531 |
|
| Pacific Biosciences of California, Inc.(a)
|
|
|
428,585 |
|
|
|
3,578,685 |
|
| QIAGEN NV(a) |
|
|
645,525 |
|
|
|
26,143,762 |
|
| Rapid Micro Biosystems, Inc., Class A(a)
|
|
|
549,778 |
|
|
|
593,760 |
|
| Repligen Corp.(a)(e) |
|
|
69,535 |
|
|
|
11,056,760 |
|
| Waters Corp.(a) |
|
|
57,155 |
|
|
|
15,672,473 |
|
| West Pharmaceutical Services, Inc.(f) |
|
|
146,255 |
|
|
|
54,876,339 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
204,852,714 |
|
|
|
| Pharmaceuticals — 7.6% |
|
|
|
|
| Adarx Pharamaceuticals, Series C, (Acquired
08/02/23, Cost: $7,160,001)(b)(c) |
|
|
860,577 |
|
|
|
7,160,001 |
|
| Arvinas, Inc.(a) |
|
|
232,960 |
|
|
|
4,575,334 |
|
| Catalent, Inc.(a) |
|
|
347,125 |
|
|
|
15,804,601 |
|
| Elanco Animal Health, Inc.(a) |
|
|
1,234,695 |
|
|
|
13,877,972 |
|
| Eli Lilly & Co. |
|
|
57,585 |
|
|
|
30,930,631 |
|
| Novo Nordisk A/S, Class B |
|
|
123,080 |
|
|
|
11,206,579 |
|
| Nuvation Bio, Inc., Class A(a) |
|
|
200,496 |
|
|
|
268,665 |
|
| Sanofi, ADR |
|
|
261,850 |
|
|
|
14,045,634 |
|
| Structure Therapeutics, Inc.(a) |
|
|
164,062 |
|
|
|
8,272,006 |
|
| Structure Therapeutics, Inc. |
|
|
283,239 |
|
|
|
3,537,655 |
|
| UCB SA |
|
|
344,377 |
|
|
|
28,207,660 |
|
| Ventyx Biosciences, Inc.(a) |
|
|
29,855 |
|
|
|
1,036,864 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
138,923,602 |
|
|
|
|
|
|
|
|
|
|
|
|
| Total Common Stocks — 89.8%
(Cost: $1,668,079,907) |
|
|
|
1,629,544,602 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Security |
|
Benefical
Interest (000) |
|
|
Value |
|
|
| Other Interests |
|
|
|
| Biotechnology — 0.1% |
|
|
|
|
| Vividion Therapeutics, Inc.(b)(c)(h) |
|
$ |
3,810 |
|
|
$ |
1,142,857 |
|
|
|
|
|
|
|
|
|
|
|
|
| Total Other Interests — 0.1%
(Cost: $ — ) |
|
|
|
1,142,857 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Shares |
|
|
|
|
|
| Preferred Securities |
|
|
|
| Preferred Stocks — 7.6% |
|
|
|
|
|
|
| Biotechnology(b)(c) — 2.7% |
|
|
|
|
| Amunix Pharmaceuticals, Inc., Series B, (Acquired
02/08/22, Cost: $0) |
|
|
5,657,068 |
|
|
|
3,563,953 |
|
| Bright Peak Therapeutics, Inc., Series B, (Acquired
05/14/21, Cost: $8,000,004) |
|
|
2,048,132 |
|
|
|
3,870,970 |
|
| Cellarity, Inc., Series B, (Acquired 01/15/21, Cost: $14,584,998) |
|
|
2,430,833 |
|
|
|
9,237,165 |
|
| Goldfinch Bio, Inc., Series B, (Acquired 06/26/20, Cost: $4,543,847) |
|
|
3,850,718 |
|
|
|
1,309,244 |
|
| Laronde, Inc., Series B, (Acquired 07/28/21, Cost: $13,498,156) |
|
|
482,077 |
|
|
|
7,033,503 |
|
| Mirvie, Inc., Series B, (Acquired 10/15/21, Cost: $6,250,000) |
|
|
2,793,833 |
|
|
|
5,727,358 |
|
| Neurogene, Inc., Series B, (Acquired 12/14/20, Cost: $9,549,916) |
|
|
3,913,900 |
|
|
|
5,596,877 |
|
| NiKang Therapeutics, Inc., Series C, (Acquired
05/20/21, Cost: $7,999,996) |
|
|
1,394,189 |
|
|
|
5,674,349 |
|
| OnKure, Inc., Series C, (Acquired 03/24/23, Cost: $7,022,595) |
|
|
2,541,380 |
|
|
|
7,014,209 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
49,027,628 |
|
|
|
| Health Care Equipment & Supplies(b)(c) — 0.8% |
|
|
|
|
| Exo Imaging, Inc., Series C, (Acquired 06/24/21, |
|
|
|
|
|
|
|
|
| Cost: $13,225,003) |
|
|
2,257,597 |
|
|
|
5,463,385 |
|
| Nucleix Ltd., Series AA, (Acquired 03/25/21, Cost: |
|
|
|
|
|
|
|
|
| $6,929,998) |
|
|
2,379,480 |
|
|
|
7,447,772 |
|
| Swift Health Systems, Inc., Series D, (Acquired 08/27/21, Cost: $6,441,930) |
|
|
2,078,042 |
|
|
|
2,555,992 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,467,149 |
|
|
|
| Health Care Providers & Services(b)(c) — 1.2% |
|
|
|
|
| Everly Well, Inc., Series D, (Acquired 11/25/20, Cost: $9,999,986) |
|
|
382,775 |
|
|
|
6,021,051 |
|
| Numab Therapeutics AG, Series C, (Acquired
05/07/21, Cost: $7,770,441) |
|
|
815,851 |
|
|
|
7,647,350 |
|
| Quanta Dialysis Technologies Ltd., Series D,
(Acquired 06/18/21, Cost: $14,071,890) |
|
|
115,766,240 |
|
|
|
7,486,058 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21,154,459 |
|
|
|
| Health Care Technology — 0.9% |
|
|
|
|
| Carbon Health Technologies, Inc., Series D2,
(Acquired 02/02/23, Cost: $17,100,000)(b)(c) |
|
|
1,694,781 |
|
|
|
16,880,019 |
|
|
|
|
|
|
|
|
|
|
|
|
| Life Sciences Tools & Services — 0.4% |
|
|
|
|
| Sartorius AG |
|
|
22,700 |
|
|
|
7,688,349 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| SCHEDULES OF INVESTMENTS |
|
2 |
|
|
|
| Schedule of Investments (unaudited) (continued)
September 30, 2023 |
|
BlackRock Health Sciences Term Trust (BMEZ)
(Percentages shown are based on Net Assets) |
|
|
|
|
|
|
|
|
|
|
|
|
| Security |
|
Shares |
|
|
Value |
|
|
| Pharmaceuticals(b)(c) — 0.7% |
|
| Insitro, Inc. |
|
|
|
|
|
|
|
|
| Series B, (Acquired 05/21/20, Cost: $4,999,999) |
|
|
802,478 |
|
|
$ |
9,774,182 |
|
| Series C, (Acquired 03/10/21, Cost: $3,600,018) |
|
|
196,818 |
|
|
|
2,397,243 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,171,425 |
|
|
| Semiconductors & Semiconductor Equipment — 0.9% |
|
| PsiQuantum Corp., Series D, (Acquired 05/21/21, Cost: $14,999,996)(b)(c) |
|
|
571,947 |
|
|
|
16,031,674 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
138,420,703 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total Preferred Securities — 7.6%
(Cost: $180,960,587) |
|
|
|
|
|
|
138,420,703 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rights |
|
|
|
|
|
|
|
|
|
| Health Care Equipment & Supplies — 0.0% |
|
| Abiomed, Inc., CVR(c) |
|
|
98,636 |
|
|
|
275,194 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total Rights — 0.0%
(Cost: $100,609) |
|
|
|
|
|
|
275,194 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants |
|
|
|
|
|
|
|
|
|
| Health Care Providers & Services — 0.0% |
|
| CareMax, Inc., (Issued/Exercisable 09/15/20, 1 Share for 1 Warrant, Expires 08/06/26, Strike
Price
USD 11.50)(a) |
|
|
63,808 |
|
|
|
12,762 |
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals — 0.0% |
|
| Nuvation Bio, Inc., (Issued/Exercisable 08/17/20, 1 Share for 1 Warrant, Expires 07/07/27, Strike
Price
USD 11.50)(a) |
|
|
68,880 |
|
|
|
6,888 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total Warrants — 0.0%
(Cost: $227,724) |
|
|
|
|
|
|
19,650 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total Long-Term Investments — 97.5%
(Cost: $1,849,368,827) |
|
|
|
|
|
|
1,769,403,006 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Short-Term Securities |
|
|
|
|
|
|
|
|
|
|
|
| Money Market Funds — 3.9% |
|
|
|
|
|
|
| BlackRock Liquidity Funds, T-Fund, Institutional Class, 5.23%(i)(j) |
|
|
58,337,342 |
|
|
|
58,337,342 |
|
| SL Liquidity Series, LLC, Money Market
Series,
5.52%(i)(j)(k) |
|
|
11,372,637 |
|
|
|
11,376,049 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total Short-Term Securities — 3.9%
(Cost: $69,709,706) |
|
|
|
|
|
|
69,713,391 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total Investments Before Options Written — 101.4%
(Cost: $1,919,078,533) |
|
|
|
|
|
|
1,839,116,397 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Options Written — (0.5)%
(Premiums Received: $(13,878,334)) |
|
|
|
|
|
|
(8,510,795 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
| Total Investments, Net of Options Written — 100.9% (Cost: $1,905,200,199) |
|
|
|
|
|
|
1,830,605,602 |
|
|
|
|
| Liabilities in Excess of Other Assets — (0.9)% |
|
|
|
|
|
|
(16,266,317 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
| Net Assets — 100.0% |
|
|
|
|
|
$ |
1,814,339,285 |
|
|
|
|
|
|
|
|
|
|
| (a) |
Non-income producing security. |
| (b) |
Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current
value of $180,839,809, representing 10.0% of its net assets as of period end, and an original cost of $224,970,628. |
| (c) |
Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value
hierarchy. |
| (d) |
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding
exchange-traded options written. |
| (e) |
All or a portion of this security is on loan. |
| (f) |
All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.
|
| (g) |
Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These
securities may be resold in transactions exempt from registration to qualified institutional investors. |
| (h) |
Other interests represent beneficial interests in liquidation trusts and other reorganization or private
entities. |
| (i) |
Affiliate of the Trust. |
| (j) |
Annualized 7-day yield as of period end. |
| (k) |
All or a portion of this security was purchased with the cash collateral from loaned securities.
|
For Trust compliance purposes,
the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the
investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.
|
|
|
| Schedule of Investments (unaudited) (continued)
September 30, 2023 |
|
BlackRock Health Sciences Term Trust (BMEZ) |
Affiliates
Investments in issuers considered to be affiliate(s) of the Trust during the period ended September 30, 2023 for purposes of
Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Affiliated Issuer |
|
Value at
12/31/22 |
|
|
Purchases
at Cost |
|
|
Proceeds
from Sales |
|
|
Net
Realized
Gain (Loss) |
|
|
Change in
Unrealized
Appreciation
(Depreciation) |
|
|
Value at
09/30/23 |
|
|
Shares
Held at
09/30/23 |
|
|
Income |
|
|
Capital Gain
Distributions
from
Underlying
Funds |
|
| BlackRock Liquidity Funds, T-Fund, Institutional
Class |
|
$ |
83,001,707 |
|
|
$ |
— |
|
|
$ |
(24,664,365) |
(a) |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
58,337,342 |
|
|
|
58,337,342 |
|
|
$ |
1,697,063 |
|
|
$ |
— |
|
| DA32 Life Science Tech Acquisition Corp.,
Class A(b) |
|
|
14,818,508 |
|
|
|
— |
|
|
|
(15,444,684 |
) |
|
|
476,494 |
|
|
|
149,682 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
| SL Liquidity Series, LLC, Money Market Series |
|
|
1,828,050 |
|
|
|
9,536,499 |
(a) |
|
|
— |
|
|
|
8,014 |
|
|
|
3,486 |
|
|
|
11,376,049 |
|
|
|
11,372,637 |
|
|
|
429,368 |
(c) |
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
484,508 |
|
|
$ |
153,168 |
|
|
$ |
69,713,391 |
|
|
|
|
|
|
$ |
2,126,431 |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
(a) |
Represents net amount purchased (sold). |
|
| |
(b) |
As of period end, the entity is no longer held. |
|
| |
(c) |
All or a portion represents securities lending income earned from the reinvestment of cash collateral from
loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities. |
|
Derivative Financial Instruments Outstanding as of Period End
Forward Foreign Currency Exchange Contracts
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Currency
Purchased |
|
|
Currency
Sold |
|
|
Counterparty |
|
Settlement Date |
|
|
Unrealized
Appreciation
(Depreciation) |
|
| USD |
|
|
6,515,074 |
|
|
EUR |
|
|
6,050,600 |
|
|
Citibank N.A. |
|
|
12/14/23 |
|
|
$ |
97,133 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CHF |
|
|
5,337,000 |
|
|
USD |
|
|
6,040,258 |
|
|
Barclays Bank PLC |
|
|
12/14/23 |
|
|
|
(163,269 |
) |
| CHF |
|
|
9,182,400 |
|
|
USD |
|
|
10,393,162 |
|
|
Barclays Bank PLC |
|
|
12/14/23 |
|
|
|
(281,700 |
) |
| JPY |
|
|
3,312,565,800 |
|
|
USD |
|
|
22,840,907 |
|
|
BNP Paribas SA |
|
|
12/14/23 |
|
|
|
(412,932 |
) |
| JPY |
|
|
3,713,189,000 |
|
|
USD |
|
|
25,601,141 |
|
|
Royal Bank of Canada |
|
|
12/14/23 |
|
|
|
(460,716 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,318,617 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
(1,221,484 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exchange-Traded Options Written
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Description |
|
Number of
Contracts |
|
|
Expiration
Date |
|
|
Exercise
Price |
|
|
Notional
Amount (000) |
|
|
Value |
|
| Call |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cencora, Inc. |
|
|
275 |
|
|
|
10/02/23 |
|
|
USD |
|
|
191.50 |
|
|
USD |
|
|
4,949 |
|
|
$ |
(8) |
|
| Avantor, Inc. |
|
|
839 |
|
|
|
10/03/23 |
|
|
USD |
|
|
22.50 |
|
|
USD |
|
|
1,769 |
|
|
|
(1,110 |
) |
| Align Technology, Inc. |
|
|
66 |
|
|
|
10/06/23 |
|
|
USD |
|
|
380.00 |
|
|
USD |
|
|
2,015 |
|
|
|
(17,160 |
) |
| Amgen, Inc. |
|
|
244 |
|
|
|
10/06/23 |
|
|
USD |
|
|
265.00 |
|
|
USD |
|
|
6,558 |
|
|
|
(134,200 |
) |
| Biogen, Inc. |
|
|
76 |
|
|
|
10/06/23 |
|
|
USD |
|
|
280.00 |
|
|
USD |
|
|
1,953 |
|
|
|
(27,360 |
) |
| Intuitive Surgical, Inc. |
|
|
73 |
|
|
|
10/06/23 |
|
|
USD |
|
|
325.00 |
|
|
USD |
|
|
2,134 |
|
|
|
(1,460 |
) |
| McKesson Corp. |
|
|
4 |
|
|
|
10/06/23 |
|
|
USD |
|
|
435.00 |
|
|
USD |
|
|
174 |
|
|
|
(1,900 |
) |
| CRISPR Therapeutics AG |
|
|
152 |
|
|
|
10/13/23 |
|
|
USD |
|
|
53.00 |
|
|
USD |
|
|
690 |
|
|
|
(2,280 |
) |
| Gilead Sciences, Inc. |
|
|
204 |
|
|
|
10/13/23 |
|
|
USD |
|
|
76.00 |
|
|
USD |
|
|
1,529 |
|
|
|
(14,586 |
) |
| Intuitive Surgical, Inc. |
|
|
75 |
|
|
|
10/13/23 |
|
|
USD |
|
|
305.00 |
|
|
USD |
|
|
2,192 |
|
|
|
(14,625 |
) |
| Vertex Pharmaceuticals, Inc. |
|
|
166 |
|
|
|
10/13/23 |
|
|
USD |
|
|
360.00 |
|
|
USD |
|
|
5,772 |
|
|
|
(33,615 |
) |
| 10X Genomics, Inc., Class A |
|
|
157 |
|
|
|
10/20/23 |
|
|
USD |
|
|
50.00 |
|
|
USD |
|
|
648 |
|
|
|
(5,103 |
) |
| Alcon, Inc. |
|
|
821 |
|
|
|
10/20/23 |
|
|
USD |
|
|
82.50 |
|
|
USD |
|
|
6,327 |
|
|
|
(45,155 |
) |
| Align Technology, Inc. |
|
|
133 |
|
|
|
10/20/23 |
|
|
USD |
|
|
335.00 |
|
|
USD |
|
|
4,061 |
|
|
|
(26,267 |
) |
| Alkermes PLC |
|
|
884 |
|
|
|
10/20/23 |
|
|
USD |
|
|
29.00 |
|
|
USD |
|
|
2,476 |
|
|
|
(41,990 |
) |
| Alkermes PLC |
|
|
488 |
|
|
|
10/20/23 |
|
|
USD |
|
|
31.00 |
|
|
USD |
|
|
1,367 |
|
|
|
(51,240 |
) |
| Alnylam Pharmaceuticals, Inc. |
|
|
284 |
|
|
|
10/20/23 |
|
|
USD |
|
|
210.00 |
|
|
USD |
|
|
5,030 |
|
|
|
(13,490 |
) |
| Amgen, Inc. |
|
|
60 |
|
|
|
10/20/23 |
|
|
USD |
|
|
270.00 |
|
|
USD |
|
|
1,613 |
|
|
|
(29,250 |
) |
| Amgen, Inc. |
|
|
60 |
|
|
|
10/20/23 |
|
|
USD |
|
|
260.00 |
|
|
USD |
|
|
1,613 |
|
|
|
(69,450 |
) |
| Apellis Pharmaceuticals, Inc. |
|
|
164 |
|
|
|
10/20/23 |
|
|
USD |
|
|
45.00 |
|
|
USD |
|
|
624 |
|
|
|
(15,990 |
) |
| Arcturus Therapeutics Holdings, Inc. |
|
|
165 |
|
|
|
10/20/23 |
|
|
USD |
|
|
40.00 |
|
|
USD |
|
|
422 |
|
|
|
(8,250 |
) |
| Argenx SE, ADR |
|
|
155 |
|
|
|
10/20/23 |
|
|
USD |
|
|
540.00 |
|
|
USD |
|
|
7,620 |
|
|
|
(62,387 |
) |
|
|
|
| SCHEDULES OF INVESTMENTS |
|
4 |
|
|
|
| Schedule of Investments (unaudited) (continued)
September 30, 2023 |
|
BlackRock Health Sciences Term Trust (BMEZ) |
Exchange-Traded Options Written (continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Description |
|
Number of
Contracts |
|
|
Expiration
Date |
|
|
Exercise
Price |
|
|
Notional
Amount (000) |
|
|
Value |
|
| Call (continued) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Arrowhead Pharmaceuticals, Inc. |
|
|
130 |
|
|
|
10/20/23 |
|
|
USD |
|
|
30.00 |
|
|
USD |
|
|
349 |
|
|
$ |
(3,250 |
) |
| Avantor, Inc. |
|
|
839 |
|
|
|
10/20/23 |
|
|
USD |
|
|
22.50 |
|
|
USD |
|
|
1,769 |
|
|
|
(20,975 |
) |
| Becton Dickinson & Co. |
|
|
65 |
|
|
|
10/20/23 |
|
|
USD |
|
|
275.00 |
|
|
USD |
|
|
1,680 |
|
|
|
(2,763 |
) |
| BeiGene Ltd., ADR |
|
|
94 |
|
|
|
10/20/23 |
|
|
USD |
|
|
220.00 |
|
|
USD |
|
|
1,691 |
|
|
|
(5,875 |
) |
| Biogen, Inc. |
|
|
76 |
|
|
|
10/20/23 |
|
|
USD |
|
|
270.00 |
|
|
USD |
|
|
1,953 |
|
|
|
(15,770 |
) |
| BioMarin Pharmaceutical, Inc. |
|
|
335 |
|
|
|
10/20/23 |
|
|
USD |
|
|
95.00 |
|
|
USD |
|
|
2,964 |
|
|
|
(25,962 |
) |
| Biomea Fusion, Inc. |
|
|
305 |
|
|
|
10/20/23 |
|
|
USD |
|
|
22.50 |
|
|
USD |
|
|
420 |
|
|
|
(6,863 |
) |
| Bio-Rad Laboratories, Inc., Class A |
|
|
64 |
|
|
|
10/20/23 |
|
|
USD |
|
|
420.00 |
|
|
USD |
|
|
2,294 |
|
|
|
(30,720 |
) |
| Bio-Techne Corp. |
|
|
400 |
|
|
|
10/20/23 |
|
|
USD |
|
|
85.00 |
|
|
USD |
|
|
2,723 |
|
|
|
(8,000 |
) |
| Blueprint Medicines Corp. |
|
|
491 |
|
|
|
10/20/23 |
|
|
USD |
|
|
60.00 |
|
|
USD |
|
|
2,466 |
|
|
|
(8,593 |
) |
| Boston Scientific Corp. |
|
|
753 |
|
|
|
10/20/23 |
|
|
USD |
|
|
52.58 |
|
|
USD |
|
|
3,976 |
|
|
|
(92,474 |
) |
| Bridgebio Pharma, Inc. |
|
|
213 |
|
|
|
10/20/23 |
|
|
USD |
|
|
35.00 |
|
|
USD |
|
|
562 |
|
|
|
(2,130 |
) |
| Bruker Corp. |
|
|
332 |
|
|
|
10/20/23 |
|
|
USD |
|
|
67.50 |
|
|
USD |
|
|
2,068 |
|
|
|
(18,260 |
) |
| Bruker Corp. |
|
|
260 |
|
|
|
10/20/23 |
|
|
USD |
|
|
65.00 |
|
|
USD |
|
|
1,620 |
|
|
|
(19,500 |
) |
| Catalent, Inc. |
|
|
555 |
|
|
|
10/20/23 |
|
|
USD |
|
|
50.00 |
|
|
USD |
|
|
2,527 |
|
|
|
(19,425 |
) |
| Cencora, Inc. |
|
|
148 |
|
|
|
10/20/23 |
|
|
USD |
|
|
191.71 |
|
|
USD |
|
|
2,664 |
|
|
|
(7,934 |
) |
| Cerevel Therapeutics Holdings, Inc. |
|
|
455 |
|
|
|
10/20/23 |
|
|
USD |
|
|
22.50 |
|
|
USD |
|
|
993 |
|
|
|
(22,750 |
) |
| Cooper Cos., Inc. |
|
|
158 |
|
|
|
10/20/23 |
|
|
USD |
|
|
390.00 |
|
|
USD |
|
|
5,025 |
|
|
|
(19,750 |
) |
| Dexcom, Inc. |
|
|
383 |
|
|
|
10/20/23 |
|
|
USD |
|
|
115.00 |
|
|
USD |
|
|
3,573 |
|
|
|
(4,788 |
) |
| Elanco Animal Health, Inc. |
|
|
1,975 |
|
|
|
10/20/23 |
|
|
USD |
|
|
13.00 |
|
|
USD |
|
|
2,220 |
|
|
|
(14,813 |
) |
| Eli Lilly & Co. |
|
|
92 |
|
|
|
10/20/23 |
|
|
USD |
|
|
590.00 |
|
|
USD |
|
|
4,942 |
|
|
|
(8,050 |
) |
| Encompass Health Corp. |
|
|
360 |
|
|
|
10/20/23 |
|
|
USD |
|
|
75.00 |
|
|
USD |
|
|
2,418 |
|
|
|
(63,000 |
) |
| Exact Sciences Corp. |
|
|
411 |
|
|
|
10/20/23 |
|
|
USD |
|
|
92.50 |
|
|
USD |
|
|
2,804 |
|
|
|
(2,055 |
) |
| Exact Sciences Corp. |
|
|
77 |
|
|
|
10/20/23 |
|
|
USD |
|
|
85.00 |
|
|
USD |
|
|
525 |
|
|
|
(3,080 |
) |
| Exelixis, Inc. |
|
|
958 |
|
|
|
10/20/23 |
|
|
USD |
|
|
23.00 |
|
|
USD |
|
|
2,093 |
|
|
|
(21,555 |
) |
| Galapagos NV, ADR |
|
|
119 |
|
|
|
10/20/23 |
|
|
USD |
|
|
40.00 |
|
|
USD |
|
|
411 |
|
|
|
(59,500 |
) |
| Gilead Sciences, Inc. |
|
|
204 |
|
|
|
10/20/23 |
|
|
USD |
|
|
76.00 |
|
|
USD |
|
|
1,529 |
|
|
|
(20,706 |
) |
| Glaukos Corp. |
|
|
91 |
|
|
|
10/20/23 |
|
|
USD |
|
|
77.50 |
|
|
USD |
|
|
685 |
|
|
|
(15,925 |
) |
| Guardant Health, Inc. |
|
|
628 |
|
|
|
10/20/23 |
|
|
USD |
|
|
40.00 |
|
|
USD |
|
|
1,861 |
|
|
|
(12,560 |
) |
| Halozyme Therapeutics, Inc. |
|
|
377 |
|
|
|
10/20/23 |
|
|
USD |
|
|
45.00 |
|
|
USD |
|
|
1,440 |
|
|
|
(3,770 |
) |
| Hologic, Inc. |
|
|
311 |
|
|
|
10/20/23 |
|
|
USD |
|
|
75.00 |
|
|
USD |
|
|
2,158 |
|
|
|
(14,773 |
) |
| Immunocore Holdings PLC, ADR |
|
|
96 |
|
|
|
10/20/23 |
|
|
USD |
|
|
65.00 |
|
|
USD |
|
|
498 |
|
|
|
(2,400 |
) |
| Incyte Corp. |
|
|
527 |
|
|
|
10/20/23 |
|
|
USD |
|
|
65.00 |
|
|
USD |
|
|
3,044 |
|
|
|
(113,305 |
) |
| Inspire Medical Systems, Inc. |
|
|
1 |
|
|
|
10/20/23 |
|
|
USD |
|
|
240.00 |
|
|
USD |
|
|
20 |
|
|
|
(65 |
) |
| Intuitive Surgical, Inc. |
|
|
165 |
|
|
|
10/20/23 |
|
|
USD |
|
|
320.00 |
|
|
USD |
|
|
4,823 |
|
|
|
(43,312 |
) |
| Ionis Pharmaceuticals, Inc. |
|
|
748 |
|
|
|
10/20/23 |
|
|
USD |
|
|
42.50 |
|
|
USD |
|
|
3,393 |
|
|
|
(250,580 |
) |
| Karuna Therapeutics, Inc. |
|
|
69 |
|
|
|
10/20/23 |
|
|
USD |
|
|
195.00 |
|
|
USD |
|
|
1,167 |
|
|
|
(6,555 |
) |
| Keros Therapeutics, Inc. |
|
|
198 |
|
|
|
10/20/23 |
|
|
USD |
|
|
37.29 |
|
|
USD |
|
|
631 |
|
|
|
(28,983 |
) |
| Legend Biotech Corp., ADR |
|
|
515 |
|
|
|
10/20/23 |
|
|
USD |
|
|
75.00 |
|
|
USD |
|
|
3,459 |
|
|
|
(57,937 |
) |
| Masimo Corp. |
|
|
295 |
|
|
|
10/20/23 |
|
|
USD |
|
|
120.00 |
|
|
USD |
|
|
2,587 |
|
|
|
(22,125 |
) |
| McKesson Corp. |
|
|
120 |
|
|
|
10/20/23 |
|
|
USD |
|
|
420.00 |
|
|
USD |
|
|
5,218 |
|
|
|
(228,600 |
) |
| Mettler-Toledo International, Inc. |
|
|
37 |
|
|
|
10/20/23 |
|
|
USD |
|
|
1,280.00 |
|
|
USD |
|
|
4,100 |
|
|
|
(8,695 |
) |
| MoonLake Immunotherapeutics, Class A |
|
|
410 |
|
|
|
10/20/23 |
|
|
USD |
|
|
70.00 |
|
|
USD |
|
|
2,337 |
|
|
|
(42,025 |
) |
| Morphic Holding, Inc. |
|
|
231 |
|
|
|
10/20/23 |
|
|
USD |
|
|
60.00 |
|
|
USD |
|
|
529 |
|
|
|
(6,930 |
) |
| Neurocrine Biosciences, Inc. |
|
|
371 |
|
|
|
10/20/23 |
|
|
USD |
|
|
110.00 |
|
|
USD |
|
|
4,174 |
|
|
|
(165,095 |
) |
| Nuvalent, Inc., Class A |
|
|
386 |
|
|
|
10/20/23 |
|
|
USD |
|
|
60.00 |
|
|
USD |
|
|
1,774 |
|
|
|
(105,185 |
) |
| Nuvalent, Inc., Class A |
|
|
386 |
|
|
|
10/20/23 |
|
|
USD |
|
|
65.00 |
|
|
USD |
|
|
1,774 |
|
|
|
(64,655 |
) |
| Omnicell, Inc. |
|
|
256 |
|
|
|
10/20/23 |
|
|
USD |
|
|
60.00 |
|
|
USD |
|
|
1,153 |
|
|
|
(6,400 |
) |
| Penumbra, Inc. |
|
|
244 |
|
|
|
10/20/23 |
|
|
USD |
|
|
270.00 |
|
|
USD |
|
|
5,903 |
|
|
|
(29,890 |
) |
| Prothena Corp. PLC |
|
|
235 |
|
|
|
10/20/23 |
|
|
USD |
|
|
65.00 |
|
|
USD |
|
|
1,134 |
|
|
|
(35,250 |
) |
| PTC Therapeutics, Inc. |
|
|
722 |
|
|
|
10/20/23 |
|
|
USD |
|
|
42.00 |
|
|
USD |
|
|
1,618 |
|
|
|
(346,560 |
) |
| Pulmonx Corp. |
|
|
350 |
|
|
|
10/20/23 |
|
|
USD |
|
|
12.50 |
|
|
USD |
|
|
362 |
|
|
|
(5,250 |
) |
| REVOLUTION Medicines, Inc. |
|
|
660 |
|
|
|
10/20/23 |
|
|
USD |
|
|
35.00 |
|
|
USD |
|
|
1,827 |
|
|
|
(330,000 |
) |
| Rhythm Pharmaceuticals, Inc. |
|
|
981 |
|
|
|
10/20/23 |
|
|
USD |
|
|
25.75 |
|
|
USD |
|
|
2,249 |
|
|
|
(48,369 |
) |
| Rocket Pharmaceuticals, Inc. |
|
|
403 |
|
|
|
10/20/23 |
|
|
USD |
|
|
17.50 |
|
|
USD |
|
|
826 |
|
|
|
(130,975 |
) |
| Sanofi, ADR |
|
|
418 |
|
|
|
10/20/23 |
|
|
USD |
|
|
57.50 |
|
|
USD |
|
|
2,242 |
|
|
|
(4,180 |
) |
| Seagen, Inc. |
|
|
170 |
|
|
|
10/20/23 |
|
|
USD |
|
|
210.00 |
|
|
USD |
|
|
3,607 |
|
|
|
(73,950 |
) |
| Shockwave Medical, Inc. |
|
|
128 |
|
|
|
10/20/23 |
|
|
USD |
|
|
230.00 |
|
|
USD |
|
|
2,548 |
|
|
|
(5,760 |
) |
| STAAR Surgical Co. |
|
|
118 |
|
|
|
10/20/23 |
|
|
USD |
|
|
46.00 |
|
|
USD |
|
|
474 |
|
|
|
(4,359 |
) |
| STERIS PLC |
|
|
255 |
|
|
|
10/20/23 |
|
|
USD |
|
|
230.00 |
|
|
USD |
|
|
5,595 |
|
|
|
(58,012 |
) |
| Stryker Corp. |
|
|
204 |
|
|
|
10/20/23 |
|
|
USD |
|
|
290.00 |
|
|
USD |
|
|
5,575 |
|
|
|
(22,950 |
) |
| Ultragenyx Pharmaceutical, Inc. |
|
|
159 |
|
|
|
10/20/23 |
|
|
USD |
|
|
40.00 |
|
|
USD |
|
|
567 |
|
|
|
(23,055 |
) |
|
|
|
| Schedule of Investments (unaudited) (continued)
September 30, 2023 |
|
BlackRock Health Sciences Term Trust (BMEZ) |
Exchange-Traded Options Written (continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Description |
|
Number of
Contracts |
|
|
Expiration
Date |
|
|
Exercise
Price |
|
|
Notional
Amount (000) |
|
|
Value |
|
| Call (continued) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| United Therapeutics Corp. |
|
|
94 |
|
|
|
10/20/23 |
|
|
|
USD |
|
|
|
240.00 |
|
|
|
USD |
|
|
|
2,123 |
|
|
$ |
(8,695 |
) |
| Vaxcyte, Inc. |
|
|
150 |
|
|
|
10/20/23 |
|
|
|
USD |
|
|
|
55.00 |
|
|
|
USD |
|
|
|
765 |
|
|
|
(22,875 |
) |
| Ventyx Biosciences, Inc. |
|
|
95 |
|
|
|
10/20/23 |
|
|
|
USD |
|
|
|
40.00 |
|
|
|
USD |
|
|
|
330 |
|
|
|
(14,725 |
) |
| Vertex Pharmaceuticals, Inc. |
|
|
222 |
|
|
|
10/20/23 |
|
|
|
USD |
|
|
|
360.00 |
|
|
|
USD |
|
|
|
7,720 |
|
|
|
(63,270 |
) |
| Viking Therapeutics, Inc. |
|
|
752 |
|
|
|
10/20/23 |
|
|
|
USD |
|
|
|
18.00 |
|
|
|
USD |
|
|
|
832 |
|
|
|
(56,400 |
) |
| Waters Corp. |
|
|
90 |
|
|
|
10/20/23 |
|
|
|
USD |
|
|
|
280.00 |
|
|
|
USD |
|
|
|
2,468 |
|
|
|
(45,000 |
) |
| West Pharmaceutical Services, Inc. |
|
|
62 |
|
|
|
10/20/23 |
|
|
|
USD |
|
|
|
390.00 |
|
|
|
USD |
|
|
|
2,326 |
|
|
|
(25,265 |
) |
| Align Technology, Inc. |
|
|
151 |
|
|
|
10/27/23 |
|
|
|
USD |
|
|
|
365.00 |
|
|
|
USD |
|
|
|
4,610 |
|
|
|
(36,617 |
) |
| Amgen, Inc. |
|
|
60 |
|
|
|
10/27/23 |
|
|
|
USD |
|
|
|
270.00 |
|
|
|
USD |
|
|
|
1,613 |
|
|
|
(35,850 |
) |
| Boston Scientific Corp. |
|
|
705 |
|
|
|
10/27/23 |
|
|
|
USD |
|
|
|
56.00 |
|
|
|
USD |
|
|
|
3,722 |
|
|
|
(22,912 |
) |
| Eli Lilly & Co. |
|
|
92 |
|
|
|
10/27/23 |
|
|
|
USD |
|
|
|
560.00 |
|
|
|
USD |
|
|
|
4,942 |
|
|
|
(55,660 |
) |
| Gilead Sciences, Inc. |
|
|
407 |
|
|
|
10/27/23 |
|
|
|
USD |
|
|
|
77.00 |
|
|
|
USD |
|
|
|
3,050 |
|
|
|
(43,549 |
) |
| Alcon, Inc. |
|
|
821 |
|
|
|
11/02/23 |
|
|
|
USD |
|
|
|
83.00 |
|
|
|
USD |
|
|
|
6,327 |
|
|
|
(40,775 |
) |
| Biogen, Inc. |
|
|
115 |
|
|
|
11/03/23 |
|
|
|
USD |
|
|
|
270.00 |
|
|
|
USD |
|
|
|
2,956 |
|
|
|
(58,075 |
) |
| Intuitive Surgical, Inc. |
|
|
124 |
|
|
|
11/03/23 |
|
|
|
USD |
|
|
|
310.00 |
|
|
|
USD |
|
|
|
3,624 |
|
|
|
(80,600 |
) |
| Align Technology, Inc. |
|
|
84 |
|
|
|
11/10/23 |
|
|
|
USD |
|
|
|
340.00 |
|
|
|
USD |
|
|
|
2,565 |
|
|
|
(71,820 |
) |
| Amgen, Inc. |
|
|
60 |
|
|
|
11/10/23 |
|
|
|
USD |
|
|
|
280.00 |
|
|
|
USD |
|
|
|
1,613 |
|
|
|
(24,000 |
) |
| 10X Genomics, Inc., Class A |
|
|
314 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
60.00 |
|
|
|
USD |
|
|
|
1,295 |
|
|
|
(47,100 |
) |
| 10X Genomics, Inc., Class A |
|
|
157 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
55.00 |
|
|
|
USD |
|
|
|
648 |
|
|
|
(5,103 |
) |
| 908 Devices, Inc. |
|
|
220 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
7.50 |
|
|
|
USD |
|
|
|
147 |
|
|
|
(13,200 |
) |
| Alcon, Inc. |
|
|
713 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
85.00 |
|
|
|
USD |
|
|
|
5,494 |
|
|
|
(190,727 |
) |
| Alkermes PLC |
|
|
885 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
33.00 |
|
|
|
USD |
|
|
|
2,479 |
|
|
|
(66,375 |
) |
| Alkermes PLC |
|
|
488 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
32.00 |
|
|
|
USD |
|
|
|
1,367 |
|
|
|
(24,400 |
) |
| Argenx SE, ADR |
|
|
155 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
540.00 |
|
|
|
USD |
|
|
|
7,620 |
|
|
|
(228,625 |
) |
| Arrowhead Pharmaceuticals, Inc. |
|
|
129 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
30.30 |
|
|
|
USD |
|
|
|
347 |
|
|
|
(9,173 |
) |
| Avantor, Inc. |
|
|
448 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
23.50 |
|
|
|
USD |
|
|
|
944 |
|
|
|
(17,490 |
) |
| Becton Dickinson & Co. |
|
|
64 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
270.00 |
|
|
|
USD |
|
|
|
1,655 |
|
|
|
(24,000 |
) |
| BeiGene Ltd., ADR |
|
|
125 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
220.00 |
|
|
|
USD |
|
|
|
2,248 |
|
|
|
(45,937 |
) |
| BioMarin Pharmaceutical, Inc. |
|
|
581 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
90.00 |
|
|
|
USD |
|
|
|
5,141 |
|
|
|
(238,210 |
) |
| Biomea Fusion, Inc. |
|
|
162 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
17.50 |
|
|
|
USD |
|
|
|
223 |
|
|
|
(19,440 |
) |
| Bio-Techne Corp. |
|
|
244 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
77.00 |
|
|
|
USD |
|
|
|
1,661 |
|
|
|
(33,934 |
) |
| Blueprint Medicines Corp. |
|
|
540 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
55.00 |
|
|
|
USD |
|
|
|
2,712 |
|
|
|
(89,100 |
) |
| Cencora, Inc. |
|
|
81 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
185.00 |
|
|
|
USD |
|
|
|
1,458 |
|
|
|
(30,375 |
) |
| Cerevel Therapeutics Holdings, Inc. |
|
|
398 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
25.00 |
|
|
|
USD |
|
|
|
869 |
|
|
|
(15,920 |
) |
| Chemed Corp. |
|
|
34 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
530.00 |
|
|
|
USD |
|
|
|
1,767 |
|
|
|
(36,890 |
) |
| CONMED Corp. |
|
|
314 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
115.00 |
|
|
|
USD |
|
|
|
3,167 |
|
|
|
(68,295 |
) |
| Cooper Cos., Inc. |
|
|
159 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
360.00 |
|
|
|
USD |
|
|
|
5,056 |
|
|
|
(16,695 |
) |
| Exelixis, Inc. |
|
|
959 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
23.00 |
|
|
|
USD |
|
|
|
2,095 |
|
|
|
(76,720 |
) |
| Galapagos NV, ADR |
|
|
119 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
40.00 |
|
|
|
USD |
|
|
|
411 |
|
|
|
(2,380 |
) |
| Halozyme Therapeutics, Inc. |
|
|
129 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
45.00 |
|
|
|
USD |
|
|
|
493 |
|
|
|
(9,030 |
) |
| Hologic, Inc. |
|
|
311 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
75.00 |
|
|
|
USD |
|
|
|
2,158 |
|
|
|
(24,102 |
) |
| Immunocore Holdings PLC, ADR |
|
|
95 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
60.00 |
|
|
|
USD |
|
|
|
493 |
|
|
|
(18,050 |
) |
| Incyte Corp. |
|
|
415 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
65.00 |
|
|
|
USD |
|
|
|
2,397 |
|
|
|
(13,488 |
) |
| Inspire Medical Systems, Inc. |
|
|
154 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
210.00 |
|
|
|
USD |
|
|
|
3,056 |
|
|
|
(152,460 |
) |
| Ionis Pharmaceuticals, Inc. |
|
|
750 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
43.62 |
|
|
|
USD |
|
|
|
3,402 |
|
|
|
(255,310 |
) |
| Keros Therapeutics, Inc. |
|
|
198 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
37.29 |
|
|
|
USD |
|
|
|
631 |
|
|
|
(38,238 |
) |
| MoonLake Immunotherapeutics, Class A |
|
|
411 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
70.00 |
|
|
|
USD |
|
|
|
2,343 |
|
|
|
(154,125 |
) |
| Morphic Holding, Inc. |
|
|
260 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
60.00 |
|
|
|
USD |
|
|
|
596 |
|
|
|
(39,000 |
) |
| Neurocrine Biosciences, Inc. |
|
|
158 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
120.00 |
|
|
|
USD |
|
|
|
1,778 |
|
|
|
(31,995 |
) |
| Omnicell, Inc. |
|
|
257 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
60.00 |
|
|
|
USD |
|
|
|
1,158 |
|
|
|
(10,923 |
) |
| Penumbra, Inc. |
|
|
103 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
308.00 |
|
|
|
USD |
|
|
|
2,492 |
|
|
|
(26,839 |
) |
| Repligen Corp. |
|
|
222 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
180.00 |
|
|
|
USD |
|
|
|
3,530 |
|
|
|
(76,590 |
) |
| REVOLUTION Medicines, Inc. |
|
|
548 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
30.00 |
|
|
|
USD |
|
|
|
1,517 |
|
|
|
(238,380 |
) |
| Rhythm Pharmaceuticals, Inc. |
|
|
1,206 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
25.60 |
|
|
|
USD |
|
|
|
2,765 |
|
|
|
(145,228 |
) |
| Rocket Pharmaceuticals, Inc. |
|
|
403 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
30.00 |
|
|
|
USD |
|
|
|
826 |
|
|
|
(8,060 |
) |
| Sanofi, ADR |
|
|
418 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
57.50 |
|
|
|
USD |
|
|
|
2,242 |
|
|
|
(18,810 |
) |
| Seagen, Inc. |
|
|
170 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
210.00 |
|
|
|
USD |
|
|
|
3,607 |
|
|
|
(146,200 |
) |
| Shockwave Medical, Inc. |
|
|
80 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
240.00 |
|
|
|
USD |
|
|
|
1,593 |
|
|
|
(25,000 |
) |
| STAAR Surgical Co. |
|
|
117 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
48.00 |
|
|
|
USD |
|
|
|
470 |
|
|
|
(12,725 |
) |
| STERIS PLC |
|
|
252 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
240.00 |
|
|
|
USD |
|
|
|
5,529 |
|
|
|
(83,160 |
) |
| Stryker Corp. |
|
|
169 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
310.00 |
|
|
|
USD |
|
|
|
4,618 |
|
|
|
(20,280 |
) |
| Ultragenyx Pharmaceutical, Inc. |
|
|
159 |
|
|
|
11/17/23 |
|
|
|
USD |
|
|
|
45.00 |
|
|
|
USD |
|
|
|
567 |
|
|
|
(19,875 |
) |
|
|
|
| SCHEDULE OF INVESTMENTS |
|
6 |
|
|
|
| Schedule of Investments (unaudited) (continued)
September 30, 2023 |
|
BlackRock Health Sciences Term Trust (BMEZ) |
Exchange-Traded Options Written (continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Description |
|
Number of
Contracts |
|
|
Expiration
Date |
|
|
Exercise
Price |
|
|
Notional
Amount (000) |
|
|
Value |
|
| Call (continued) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| United Therapeutics Corp. |
|
|
84 |
|
|
|
11/17/23 |
|
|
USD |
|
|
240.00 |
|
|
USD |
|
|
1,897 |
|
|
$ |
(35,280 |
) |
| Vaxcyte, Inc. |
|
|
325 |
|
|
|
11/17/23 |
|
|
USD |
|
|
55.00 |
|
|
USD |
|
|
1,657 |
|
|
|
(78,812 |
) |
| Vertex Pharmaceuticals, Inc. |
|
|
176 |
|
|
|
11/17/23 |
|
|
USD |
|
|
370.00 |
|
|
USD |
|
|
6,120 |
|
|
|
(90,640 |
) |
| West Pharmaceutical Services, Inc. |
|
|
367 |
|
|
|
11/17/23 |
|
|
USD |
|
|
410.00 |
|
|
USD |
|
|
13,770 |
|
|
|
(194,510 |
) |
| Cencora, Inc. |
|
|
115 |
|
|
|
12/15/23 |
|
|
USD |
|
|
195.00 |
|
|
USD |
|
|
2,070 |
|
|
|
(21,563 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
(7,458,702 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OTC Options Written
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Description |
|
Counterparty |
|
Number of
Contracts |
|
|
Expiration
Date |
|
|
Exercise
Price |
|
|
Notional
Amount (000) |
|
|
Value |
|
| Call |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Alkermes PLC |
|
Goldman Sachs International |
|
|
63,700 |
|
|
|
10/02/23 |
|
|
|
USD |
|
|
|
29.71 |
|
|
|
USD |
|
|
|
1,784 |
|
|
$ |
(503 |
) |
| ConvaTec Group PLC |
|
Goldman Sachs International |
|
|
411,500 |
|
|
|
10/03/23 |
|
|
|
GBP |
|
|
|
2.31 |
|
|
|
GBP |
|
|
|
894 |
|
|
|
(60 |
) |
| UCB SA |
|
Morgan Stanley & Co. International PLC |
|
|
13,800 |
|
|
|
10/03/23 |
|
|
|
EUR |
|
|
|
83.05 |
|
|
|
EUR |
|
|
|
1,069 |
|
|
|
(25 |
) |
| Abcam PLC, ADR |
|
Barclays Bank PLC |
|
|
78,100 |
|
|
|
10/05/23 |
|
|
|
USD |
|
|
|
22.98 |
|
|
|
USD |
|
|
|
1,767 |
|
|
|
(33,756 |
) |
| Waters Corp. |
|
Barclays Bank PLC |
|
|
9,200 |
|
|
|
10/06/23 |
|
|
|
USD |
|
|
|
286.00 |
|
|
|
USD |
|
|
|
2,523 |
|
|
|
(5,938 |
) |
| Straumann Holding AG, Registered Shares |
|
Goldman Sachs International |
|
|
30,800 |
|
|
|
10/13/23 |
|
|
|
CHF |
|
|
|
137.67 |
|
|
|
CHF |
|
|
|
3,588 |
|
|
|
(256 |
) |
| Genmab A/S, ADR |
|
Morgan Stanley & Co. International PLC |
|
|
36,500 |
|
|
|
10/17/23 |
|
|
|
USD |
|
|
|
38.68 |
|
|
|
USD |
|
|
|
1,287 |
|
|
|
(11,351 |
) |
| ConvaTec Group PLC |
|
UBS AG |
|
|
490,000 |
|
|
|
10/19/23 |
|
|
|
GBP |
|
|
|
2.43 |
|
|
|
GBP |
|
|
|
1,064 |
|
|
|
(556 |
) |
| Genmab A/S, ADR |
|
Goldman Sachs International |
|
|
1,900 |
|
|
|
10/19/23 |
|
|
|
DKK |
|
|
|
2,715.07 |
|
|
|
DKK |
|
|
|
4,746 |
|
|
|
(2,347 |
) |
| Gerresheimer AG |
|
UBS AG |
|
|
20,000 |
|
|
|
10/19/23 |
|
|
|
EUR |
|
|
|
126.42 |
|
|
|
EUR |
|
|
|
1,982 |
|
|
|
(1,007 |
) |
| 908 Devices, Inc. |
|
Barclays Bank PLC |
|
|
21,900 |
|
|
|
10/20/23 |
|
|
|
USD |
|
|
|
7.53 |
|
|
|
USD |
|
|
|
146 |
|
|
|
(2,624 |
) |
| Gerresheimer AG |
|
UBS AG |
|
|
14,900 |
|
|
|
10/25/23 |
|
|
|
EUR |
|
|
|
108.55 |
|
|
|
EUR |
|
|
|
1,477 |
|
|
|
(21,291 |
) |
| Sartorius AG |
|
Goldman Sachs International |
|
|
7,200 |
|
|
|
10/25/23 |
|
|
|
EUR |
|
|
|
340.73 |
|
|
|
EUR |
|
|
|
2,307 |
|
|
|
(55,726 |
) |
| UCB SA |
|
UBS AG |
|
|
55,000 |
|
|
|
10/25/23 |
|
|
|
EUR |
|
|
|
84.27 |
|
|
|
EUR |
|
|
|
4,261 |
|
|
|
(15,989 |
) |
| UCB SA |
|
Goldman Sachs International |
|
|
27,600 |
|
|
|
10/31/23 |
|
|
|
EUR |
|
|
|
85.31 |
|
|
|
EUR |
|
|
|
2,138 |
|
|
|
(8,539 |
) |
| Elanco Animal Health, Inc. |
|
Goldman Sachs International |
|
|
98,800 |
|
|
|
11/01/23 |
|
|
|
USD |
|
|
|
12.97 |
|
|
|
USD |
|
|
|
1,111 |
|
|
|
(15,916 |
) |
| Masimo Corp. |
|
UBS AG |
|
|
17,000 |
|
|
|
11/02/23 |
|
|
|
USD |
|
|
|
110.24 |
|
|
|
USD |
|
|
|
1,491 |
|
|
|
(19,074 |
) |
| Legend Biotech Corp., ADR |
|
UBS AG |
|
|
49,600 |
|
|
|
11/06/23 |
|
|
|
USD |
|
|
|
69.81 |
|
|
|
USD |
|
|
|
3,332 |
|
|
|
(177,288 |
) |
| Gerresheimer AG |
|
UBS AG |
|
|
14,900 |
|
|
|
11/08/23 |
|
|
|
EUR |
|
|
|
110.25 |
|
|
|
EUR |
|
|
|
1,477 |
|
|
|
(24,021 |
) |
| MorphoSys AG |
|
Morgan Stanley & Co. International PLC |
|
|
16,200 |
|
|
|
11/08/23 |
|
|
|
EUR |
|
|
|
30.47 |
|
|
|
EUR |
|
|
|
417 |
|
|
|
(31,419 |
) |
| Novo Nordisk A/S, Class B |
|
Goldman Sachs International |
|
|
19,700 |
|
|
|
11/08/23 |
|
|
|
DKK |
|
|
|
666.32 |
|
|
|
DKK |
|
|
|
12,654 |
|
|
|
(48,460 |
) |
| ConvaTec Group PLC |
|
Morgan Stanley & Co. International PLC |
|
|
510,000 |
|
|
|
11/09/23 |
|
|
|
GBP |
|
|
|
2.24 |
|
|
|
GBP |
|
|
|
1,108 |
|
|
|
(28,232 |
) |
| Gerresheimer AG |
|
UBS AG |
|
|
28,000 |
|
|
|
11/09/23 |
|
|
|
EUR |
|
|
|
103.99 |
|
|
|
EUR |
|
|
|
2,775 |
|
|
|
(97,122 |
) |
| QIAGEN NV |
|
Citibank N.A. |
|
|
206,400 |
|
|
|
11/13/23 |
|
|
|
USD |
|
|
|
42.94 |
|
|
|
USD |
|
|
|
8,359 |
|
|
|
(208,204 |
) |
| Bavarian Nordic A/S |
|
Goldman Sachs International |
|
|
12,000 |
|
|
|
11/14/23 |
|
|
|
DKK |
|
|
|
166.98 |
|
|
|
DKK |
|
|
|
1,894 |
|
|
|
(11,346 |
) |
| Novo Nordisk A/S, Class B |
|
Morgan Stanley & Co. International PLC |
|
|
19,600 |
|
|
|
11/14/23 |
|
|
|
DKK |
|
|
|
676.10 |
|
|
|
DKK |
|
|
|
12,589 |
|
|
|
(46,668 |
) |
| Genmab A/S, ADR |
|
Goldman Sachs International |
|
|
9,200 |
|
|
|
11/16/23 |
|
|
|
DKK |
|
|
|
2,653.28 |
|
|
|
DKK |
|
|
|
22,978 |
|
|
|
(79,347 |
) |
| UCB SA |
|
Goldman Sachs International |
|
|
13,800 |
|
|
|
11/16/23 |
|
|
|
EUR |
|
|
|
81.56 |
|
|
|
EUR |
|
|
|
1,069 |
|
|
|
(22,815 |
) |
| Glaukos Corp. |
|
Citibank N.A. |
|
|
26,200 |
|
|
|
11/27/23 |
|
|
|
USD |
|
|
|
81.52 |
|
|
|
USD |
|
|
|
1,972 |
|
|
|
(82,213 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
(1,052,093 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. These inputs to valuation techniques are categorized into a fair
value hierarchy consisting of three broad levels for financial reporting purposes as follows:
| |
• |
|
Level 1 – Unadjusted price quotations in active markets/exchanges for identical assets or liabilities
that the Trust has the ability to access; |
| |
• |
|
Level 2 – Other observable inputs (including, but not limited to, quoted prices for similar assets or
liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield
curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market–corroborated inputs); and |
| |
• |
|
Level 3 – Unobservable inputs based on the best information available in the circumstances, to the
extent observable inputs are not available (including the Valuation Committee’s assumptions used in determining the fair value of financial instruments). |
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements)
and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The
|
|
|
| Schedule of Investments (unaudited) (continued)
September 30, 2023 |
|
BlackRock Health Sciences Term Trust (BMEZ) |
Fair Value Hierarchy as of Period End (continued)
inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair
value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Investments classified within Level 3 have significant unobservable inputs used by the Valuation
Committee in determining the price for Fair Valued Investments. Level 3 investments include equity or debt issued by privately held companies or funds. There may not be a secondary market, and/or there are a limited number of investors. The
categorization of a value determined for financial instruments is based on the pricing transparency of the financial instruments and is not necessarily an indication of the risks associated with investing in those securities. For information about
the Trust’s policy regarding valuation of financial instruments, refer to its most recent financial statements.
Certain investments of
the Trust were fair valued using net asset value (“NAV”) as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s
financial instruments into major categories is disclosed in the Schedule of Investments above.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
| Assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Long-Term Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stocks |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Biotechnology |
|
$ |
723,035,364 |
|
|
$ |
26,068,138 |
|
|
$ |
19,964,409 |
|
|
$ |
769,067,911 |
|
| Electronic Equipment, Instruments & Components |
|
|
1,825,399 |
|
|
|
— |
|
|
|
— |
|
|
|
1,825,399 |
|
| Health Care Equipment & Supplies |
|
|
385,605,025 |
|
|
|
23,928,531 |
|
|
|
— |
|
|
|
409,533,556 |
|
| Health Care Providers & Services |
|
|
83,296,300 |
|
|
|
21,301,833 |
|
|
|
— |
|
|
|
104,598,133 |
|
| Health Care Technology |
|
|
743,287 |
|
|
|
— |
|
|
|
— |
|
|
|
743,287 |
|
| Life Sciences Tools & Services |
|
|
179,358,925 |
|
|
|
25,493,789 |
|
|
|
— |
|
|
|
204,852,714 |
|
| Pharmaceuticals |
|
|
88,811,707 |
|
|
|
42,951,894 |
|
|
|
7,160,001 |
|
|
|
138,923,602 |
|
| Other Interests |
|
|
— |
|
|
|
— |
|
|
|
1,142,857 |
|
|
|
1,142,857 |
|
| Preferred Securities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred Stocks |
|
|
— |
|
|
|
7,688,349 |
|
|
|
130,732,354 |
|
|
|
138,420,703 |
|
| Rights |
|
|
— |
|
|
|
— |
|
|
|
275,194 |
|
|
|
275,194 |
|
| Warrants |
|
|
19,650 |
|
|
|
— |
|
|
|
— |
|
|
|
19,650 |
|
| Short-Term Securities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Money Market Funds |
|
|
58,337,342 |
|
|
|
— |
|
|
|
— |
|
|
|
58,337,342 |
|
| Liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Unfunded SPAC PIPE Commitments(a) |
|
|
— |
|
|
|
— |
|
|
|
(129,923 |
) |
|
|
(129,923 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
1,521,032,999 |
|
|
$ |
147,432,534 |
|
|
$ |
159,144,892 |
|
|
|
1,827,610,425 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Investments Valued at NAV(b) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,376,049 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
1,838,986,474 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Derivative Financial Instruments(c) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Foreign Currency Exchange Contracts |
|
$ |
— |
|
|
$ |
97,133 |
|
|
$ |
— |
|
|
$ |
97,133 |
|
| Liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Equity Contracts |
|
|
(6,695,753 |
) |
|
|
(1,815,042 |
) |
|
|
— |
|
|
|
(8,510,795 |
) |
| Foreign Currency Exchange Contracts |
|
|
— |
|
|
|
(1,318,617 |
) |
|
|
— |
|
|
|
(1,318,617 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
(6,695,753 |
) |
|
$ |
(3,036,526 |
) |
|
$ |
— |
|
|
$ |
(9,732,279 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
(a) |
Unfunded SPAC PIPE commitments are valued at the unrealized appreciation (depreciation) on the commitment.
|
|
| |
(b) |
Certain investments of the Trust were fair valued using NAV as a practical expedient as no quoted market value
is available and therefore have been excluded from the fair value hierarchy. |
|
| |
(c) |
Derivative financial instruments are forward foreign currency exchange contracts and options written. Forward
foreign currency exchange contracts are valued at the unrealized appreciation (depreciation) on the instrument and options written are shown at value. |
|
A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount
of Level 3 investments and derivative financial instruments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were
used in determining fair value:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Common
Stocks |
|
|
Other
Interests |
|
|
Preferred
Stocks |
|
|
Rights |
|
|
Unfunded
SPAC
PIPE Commitments |
|
|
Total |
|
| Assets/Liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Opening balance, as of December 31, 2022 |
|
$ |
12,093,187 |
|
|
$ |
4,076,191 |
|
|
$ |
158,791,702 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
174,961,080 |
|
| Transfers into Level 3 |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
| Transfers out of Level 3 |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
| SCHEDULE OF INVESTMENTS |
|
8 |
|
|
|
| Schedule of Investments (unaudited) (continued)
September 30, 2023 |
|
BlackRock Health Sciences Term Trust (BMEZ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Common
Stocks |
|
|
Other
Interests |
|
|
Preferred
Stocks |
|
|
Rights |
|
|
Unfunded
SPAC PIPE
Commitments |
|
|
Total |
|
| Other(a) |
|
$ |
(9,726,707 |
) |
|
$ |
— |
|
|
$ |
9,626,098 |
|
|
$ |
100,609 |
|
|
$ |
— |
|
|
$ |
— |
|
| Accrued discounts/premiums |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
| Net realized gain (loss) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
| Net change in unrealized appreciation (depreciation)(b)
|
|
|
58,064 |
|
|
|
(2,933,334 |
) |
|
|
(22,368,042 |
) |
|
|
174,585 |
|
|
|
(129,923 |
) |
|
|
(25,198,650 |
) |
| Purchases |
|
|
24,699,866 |
|
|
|
— |
|
|
|
24,122,597 |
|
|
|
— |
|
|
|
— |
|
|
|
48,822,463 |
|
| Sales |
|
|
— |
|
|
|
— |
|
|
|
(39,440,001 |
) |
|
|
— |
|
|
|
— |
|
|
|
(39,440,001 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Closing balance, as of September 30, 2023 |
|
$ |
27,124,410 |
|
|
$ |
1,142,857 |
|
|
$ |
130,732,354 |
|
|
$ |
275,194 |
|
|
$ |
(129,923 |
) |
|
$ |
159,144,892 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net change in unrealized appreciation (depreciation) on investments still held at September 30,
2023(b) |
|
$ |
58,064 |
|
|
$ |
(2,933,334 |
) |
|
$ |
(16,911,702 |
) |
|
$ |
174,585 |
|
|
$ |
(129,923 |
) |
|
$ |
(19,742,310 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
(a) |
Certain Level 3 investments were re-classified between Common
Stocks,Preferred Stocks and Rights. |
|
| |
(b) |
Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized
appreciation (depreciation) on investments still held at September 30, 2023 is generally due to investments no longer held or categorized as Level 3 at period end. |
|
The following table summarizes the valuation approaches used and unobservable inputs utilized by the
BlackRock Valuation Committee (the “Valuation Committee”) to determine the value of certain of the Trust’s Level 3 financial instruments as of period end. The table does not include Level 3 financial instruments with values
based upon unadjusted third-party pricing information in the amount of $129,923. A significant change in third party information could result in a significantly lower or higher value of such Level 3 financial instruments.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Value |
|
|
Valuation
Approach |
|
|
Unobservable Inputs |
|
|
Range
of
Unobservable
Inputs Utilized(a) |
|
|
Weighted
Average of
Unobservable
Inputs Based
on Fair
Value |
|
| Assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock |
|
$ |
27,124,410 |
|
|
|
Income |
|
|
|
Discount Rate |
|
|
|
5% - 6% |
|
|
|
6 |
% |
|
|
|
|
|
|
|
Market |
|
|
|
Market Adjustment Multiple |
|
|
|
1.00x - 1.00x |
|
|
|
1.00x |
|
|
|
|
|
|
|
|
|
|
|
|
Volatility |
|
|
|
80% - 90% |
|
|
|
84 |
% |
|
|
|
|
|
|
|
|
|
|
|
Time to Exit |
|
|
|
2.0 -3.0 years |
|
|
|
2.6 years |
|
|
|
|
|
|
|
| Preferred Stocks |
|
|
130,732,354 |
|
|
|
Market |
|
|
|
Revenue Multiple |
|
|
|
2.50x - 7.00x |
|
|
|
5.82x |
|
|
|
|
|
|
|
|
|
|
|
|
Volatility |
|
|
|
50% - 100% |
|
|
|
70 |
% |
|
|
|
|
|
|
|
|
|
|
|
Time to Exit |
|
|
|
0.3 - 4.0 years |
|
|
|
2.4 years |
|
|
|
|
|
|
|
|
|
|
|
|
Market Adjustment Multiple |
|
|
|
0.40x - 1.20x |
|
|
|
0.89x |
|
|
|
|
|
|
|
|
Income |
|
|
|
Discount Rate |
|
|
|
6% - 6% |
|
|
|
6 |
% |
|
|
|
|
|
|
| Other Interests |
|
|
1,142,857 |
|
|
|
Income |
|
|
|
Discount Rate |
|
|
|
7 |
% |
|
|
— |
|
|
|
|
|
|
|
| Rights |
|
|
275,194 |
|
|
|
Income |
|
|
|
Discount Rate |
|
|
|
5 |
% |
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
159,274,815 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
(a) |
A significant change in unobservable input would have resulted in a correlated (inverse) significant change to
value. |
|
|
|
|
| Currency Abbreviation |
|
|
| CHF |
|
Swiss Franc |
| DKK |
|
Danish Krone |
| EUR |
|
Euro |
| GBP |
|
British Pound |
| JPY |
|
Japanese Yen |
| USD |
|
United States Dollar |
|
|
|
| Portfolio Abbreviation |
|
|
| ADR |
|
American Depositary Receipt |
| CVR |
|
Contingent Value Right |
| PIPE |
|
Private Investment in Public Equity |
| SPAC |
|
Special Purpose Acquisition Company |
BlackRock Health Science... (NYSE:BMEZ)
Historical Stock Chart
From May 2024 to Jun 2024
BlackRock Health Science... (NYSE:BMEZ)
Historical Stock Chart
From Jun 2023 to Jun 2024
